

Starogard Gd., 08.09.2025

PRICE INQUIRY No. SEMA 70/PR113719/2025
conducted by means of market discernment

In connection with the implementation of the project titled 'Development and advancement of an innovative solution - a generic drug from the group of GLP-1 receptor agonists in the treatment of type 2 diabetes,' financed by state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A. are requesting bids for the provision of services for conducting analytical tests described in detail in point. III.

I. NAME AND ADDRESS OF THE ORDERING PARTY

Zakłady Farmaceutyczne Polpharma S.A.
Pelplinska St. 19, 83-20 0 Starogard Gdanski

II. MODE OF AWARDING THE CONTRACT

- 2.1. This order is not subject to the provisions of the Act of September 11, 2019. Public Procurement Law (i.e. Journal of Laws of 2019, item 2019)
- 2.2. Proceedings conducted by market discernment, in an expedient and economical manner in compliance with the rules:
 - 2.2.1. getting the best results from given inputs;
 - 2.2.2. optimal selection of methods and means to achieve the objectives;
 - 2.2.3. openness, fair competition and equal treatment of contractors.

III. DESCRIPTION OF THE SUBJECT OF THE PRICE INQUIRY

III.1. The subject of the request for quotation is the purchase of a research service related to:

- development of the feasibility of analytical methods for the characterization of the active substance and the finished product containing the active substance semaglutide in the concentration range of 0.68 – 3.2 mg/ml,
- validation of previously developed methods for minimum two concentrations,
- conducting comparative analyses against the reference product according to previously developed methodology in GMP quality,
- conducting routine analyses in GMP and non-GMP quality.

III.2. CPV CODE: 73100000-9 Research and experimental development services

III.3. Scope of the request for quotation: The request consists of four items:

- a) Development of the feasibility of analytical methods,
- b) Validation of analytical methods,
- c) Conducting comparative studies, and
- d) Conducting routine studies.

The purchaser reserves the right to implement the various stages in parallel and in any order depending on the progress of the R&D project.

III.3.1. Development of the feasibility of analytical methods along with the preparation of test samples to demonstrate the similarity of the product under pharmaceutical development (also referred to as the test product) to the reference product for the active substance using the following techniques:

- Nuclear Magnetic Resonance (1D NMR, 2D NMR)
- Differential Scanning Calorimetry (DSC)
- Circular Dichroism (far and near CD)
- Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC)

The designed scope of method development should demonstrate that the proposed analytical methods are suitable in terms of discriminatory capability as well as sensitivity and resolution, with particular emphasis on tests such as specificity and repeatability for the active substance and the finished product.

III.3.1.1. Testing of the test product (finished product and/or active substance) against the reference product using the developed methods.

III.3.1.2. Delivery of a method development report including results and raw data for the tested samples.

III.3.1.3. Delivery of final descriptions of the developed methods.

III.3.1.4. Ensuring that the developed analytical methods are conducted within a quality system compliant with GMP rules.

III.3.1.5. The Ordering Party shall provide the materials necessary for method development in quantities sufficient to demonstrate the suitability of the developed methods.

III.3.1.6. The Ordering Party reserves the right to commission analyses for all techniques or only for selected methods chosen by the Ordering Party.

The purchaser reserves the right to implement the various stages in parallel and in any order depending on the progress of the R&D project.

III.3.2. Perform validation of developed analytical methods for the product and active substance under pharmaceutical development in terms of techniques and in terms of requirements:

- Nuclear magnetic resonance (1D NMR, 2D NMR),
- Differential scanning calorimetry (DSC),
- circular dichroism (CD),
- Sedimentation velocity by ultracentrifugation (SV-AUC).

III.3.2.1. For the circular dichroism (CD) method:

Objective of the method:
Study of higher order structures in the product performed on a circular dichroism (CD) spectrometer
Scope:
The method should be specific in terms of the presence of higher-order structures and should give the opportunity to compare products against each other.
Parameters of the conducted method to be included in the report:
Specificity of the analytical method (minimum scope of test: vehiculum, two test samples with different concentrations, negative sample).
Repeatability of the analytical method (minimum of six test samples) for minimum two concentrations.

III.3.2.2. For the method, differential scanning calorimetry (DSC):

Objective of the method:
Study of higher-order structures in the product performed on a differential scanning calorimeter (nano DSC).
Scope:
The method should be specific in terms of the presence of higher-order structures and should give the opportunity to compare products against each other.
Parameters of the conducted method to be included in the report:
Specificity of the analytical method (minimum scope of test: vehiculum, two test samples with different concentrations, negative sample).
Repeatability of the analytical method (minimum of six test samples) for minimum two concentrations.

III.3.2.3. For the method, sedimentation velocity by ultracentrifugation (SV-AUC):

Objective of the method:
Study of higher-order structures in the product performed on an analytical ultracentrifuge (SV-AUC).
Scope:
The method should be specific in terms of the presence of higher-order structures and should give the opportunity to compare products against each other.
Parameters of the conducted method to be included in the report:
Specificity of the analytical method (minimum scope of test: vehiculum, two test samples with different concentrations, negative sample).
Repeatability of the analytical method (minimum of six test samples) for minimum two concentrations.

III.3.2.4. For the nuclear magnetic resonance method (1D, 2D NMR):

Objective of the method:
Study of the structure in the product performed on a nuclear magnetic resonance spectrometer (NMR 600 MHz)
Scope:
The method should be specific for the characterization of higher-order structures and should provide an opportunity to compare products against each other.
Parameters of the conducted method to be included in the report:
Specificity of the analytical method (minimum scope of test: vehiculum, two test samples with different concentrations, negative sample)
Repeatability of the analytical method (minimum of six test samples) for minimum two concentrations

III.3.2.5. The basic order includes validation of analytical methods, which should be carried out in accordance with the ICH Q2(R2) guideline. The minimum scope of validation includes specificity/selectivity (confirmed by negative samples) and method repeatability.

III.3.2.6. The Ordering Party reserves the right to award additional orders in the event of the need to test additional samples as part of method validation. Additional samples will be ordered by the Ordering Party after agreeing with the Contractor on the scope of the study and the delivery date.

III.3.2.7. Validation protocols (plans) for methods (including a description of sample preparation and the number of samples tested) should be submitted for approval by the Ordering Party before conducting the tests.

III.3.2.8. The Ordering Party requires the delivery of a validation report of the methods along with results and raw data for the tested samples after the study is completed.

III.3.2.9. The Ordering Party requires the Bidder to propose, based on the conducted validation, acceptance criteria for the comparative study of products (test product vs. reference product).

III.3.2.10. The Bidder is obliged to ensure that validated analytical methods are conducted in a quality system compliant with GMP.

III.3.2.11. The Ordering Party reserves the right to commission analyses for all techniques or only for individual methods selected by the Ordering Party.

III.3.2.12. The Ordering Party reserves the right to commission additional analyses multiple times, specifying the scope of the study and the number of samples with each order. Samples for testing will be delivered in batches depending on the needs of the Ordering Party.

III.3.3. Conducting a comparative study of the test product against the reference product (sameness) along with the preparation of tested samples using validated methods.

III.3.3.1. At the offer submission stage, the pricing includes comparative studies for 6 series for each of the above-mentioned techniques. The final number of series will be determined during the study implementation. Acceptance criteria for the comparative study should be agreed with the Ordering Party.

III.3.3.2. The Ordering Party reserves the right to award additional orders in the event of the need to test additional series. Additional samples will be ordered by the Ordering Party after agreeing with the Contractor on the scope of the study and the delivery date.

III.3.3.3. The Ordering Party requires the delivery of a comparative study report along with raw data for the tested samples and a description of the equipment used for the analyses after the study is completed.

III.3.3.4. The Bidder is obliged to ensure that the study is conducted in a quality system compliant with GMP.

III.3.3.5. The Ordering Party reserves the right to commission analyses for the entire item or only for individual methods selected by the Ordering Party.

III.3.3.6. The Ordering Party reserves the right to commission additional analyses multiple times, specifying the scope of the study and the number of samples with each order. Samples for testing will be delivered in batches depending on the needs of the Ordering Party.

III.3.4. Conducting routine GMP and non-GMP studies along with the preparation of tested samples, scope of analyses:

- nuclear magnetic resonance (1D, 2D),
- differential scanning calorimetry (DSC),
- circular dichroism (CD),
- sedimentation velocity by ultracentrifugation (SV-AUC)

III.3.4.1. The studies will be conducted multiple times during the contract period, for a minimum of 1 series and as additional samples, and the number of samples for testing will be consulted with the Contractor before sending them for testing.

III.3.4.2. The Bidder is obliged to ensure that the studies are conducted in a quality system compliant with GMP.

III.3.4.3. The Ordering Party requires the delivery of a report with a description and parameters of the conducted method, results, and raw data for the tested samples after the study is completed.

III.3.4.4. The Contractor will conduct studies of the active substance series, test product, or reference product during the research project period – until March 31, 2027.

III.3.4.5. The Ordering Party reserves the right to commission analyses for the entire item or only for individual methods selected by the Ordering Party.

III.3.4.6. The Ordering Party reserves the right to commission analyses multiple times, specifying the scope of the study and the number of samples with each order. Samples for testing will be delivered in batches depending on the needs of the Ordering Party.

III.3.5. The Ordering Party does not allow partial or variant offers.

III.3.6. The Ordering Party will provide the product, vehicle, and necessary materials to demonstrate specificity in the case of method validation in quantities sufficient to perform the service.

III.3.7. At any stage of service implementation, the Ordering Party may withdraw from further implementation if the results of a given stage do not meet the Ordering Party's requirements. The Contractor may not claim compensation for this reason.

IV. PLACE AND DATE OF EXECUTION OF THE PRICE INQUIRY

4.1. Planned contract /order signing date: September / October 2025.

- 4.2. The planned period of performance of the subject of the price inquiry is set at 24 months from the date of contract/order signing, with the possibility of extension.
- 4.3. The planned execution period for the subject of the request for quotation:
- no longer than 8 weeks counted from the date all samples are delivered to the bidder's laboratory to the submission of the analytical method development report,
 - no longer than 12 weeks counted from the date all samples are delivered to the bidder's laboratory to the submission of the analytical method validation report,
 - no longer than 5 weeks from the date the samples are delivered to the submission of the comparative study report,
 - no longer than 5 weeks from the date the samples are delivered to the submission of the routine analysis report.
- 4.4. The organization and cost of shipping samples for testing is the responsibility of the Ordering Party.

V. REQUIREMENTS FROM CONTRACTORS

5.1. Contractors who meet the following conditions may apply for the award of the contract:

- 5.1.1. They possess at least 3 years of knowledge and experience in conducting comparative NMR studies for polypeptides.
- 5.1.2. They possess knowledge and at least 3 years of experience in conducting comparative analytical method studies using DSC, CD, and SV-AUC techniques for polypeptides.
- 5.1.3. The laboratory holds GMP certification for the analytical techniques that are the subject of this inquiry.
- 5.1.4. Entities subject to the following circumstances are excluded from participation in the procedure:
- a) as described in Article 7(1) of the Act of April 13, 2022, on special solutions for counteracting support for aggression against Ukraine and for the protection of national security;
 - b) as described in Article 5k of Council Regulation (EU) No. 833/2014 of July 31, 2014, concerning restrictive measures in view of Russia's actions destabilizing the situation in Ukraine.

How to evaluate the condition:

The Contracting Authority will consider that the Contractor meets this condition if the Contractor submits a statement of fulfillment of the conditions for participation in the proceedings (Appendix No. 2 to the Price Inquiry).

The contracting authority reserves the right to verify the fulfillment of conditions at the bidder's premises or to call for relevant documentation.

VI. PLACE AND DEADLINE FOR SUBMITTING BIDS

6.1. Bids must be submitted by the deadline of **15.09.2025**.

- in electronic form (in the form of a scan of the signed document) to the address:
beata.zywicka@polpharma.com

Submission of a bid will be considered successful if a complete bid is received at the e-mail box with the above address by the deadline specified in this section.

6.2. Bids submitted after the deadline will not be considered.

VII. DESCRIPTION OF PRICE CALCULATION

7.1. How to calculate the bid price: the price should be calculated net and gross.



7.2. For evaluation, bids submitted in a currency other than PLN will be converted into PLN at the average exchange rate of the National Bank of Poland (<https://www.nbp.pl/>) on the closing date for submission of bids.

7.3. The price should include all costs associated with the preparation and execution of the subject of the request.

7.4. The price submitted in the bid cannot be changed during the execution of the contract.

VIII. DESCRIPTION OF THE CRITERIA THAT THE CONTRACTING AUTHORITY WILL BE GUIDED BY WHEN SELECTING A BID

8.1. In evaluating bids, the Contracting Authority will be guided by the criteria listed:

- total net order price - 100%

8.2. The scoring of the bid will be done according to the formula:

$$O_P = P_C \quad \text{Where:}$$

O_P - offer scoring

P_C - number of points obtained in the criterion "Total net order price"

8.3. The number of points (P_C) in the criterion "Total net order price" will be calculated according to the formula:

$$P_C = \frac{C_N}{C_B} * 100 \text{ pkt}$$

Where:

- | | |
|-------|--|
| P_C | ○ Number of points for the criterion "Total net order price" |
| C_N | ○ of the non-rejected bids, the lowest total net bid price |
| C_B | ○ total net price of the tested offer |

8.4. The maximum the Bidder can obtain is 100 points. Calculations will be made to two decimal places.

Bids submitted in a currency other than PLN will be converted into PLN at the average exchange rate of the National Bank of Poland on the closing date for submission of bids.

IX. DESCRIPTION OF BID PREPARATION

9.1. The bidder should prepare one price offer in accordance with the model form attached as Annex 1 to the request.

9.2. **The bid should be signed by persons authorized to represent the Bidder by virtue of entries in the relevant registers or by power of attorney. The power of attorney should be attached to the bid.**

9.3. The offer is valid for 90 days from the deadline for submitting offer.

9.4. The bidder may amend or withdraw its bid before the deadline for submission of bids.

9.5. Bidders are required to carefully review the information contained in the Price Inquiry.

9.6. The cost of preparation and delivery of the bid shall be borne by the Contractor.

9.7. For matters related to this inquiry, please contact the Contracting Authority, e-mail: beata.zywicka@polpharma.com

9.8. The minimum invoice payment term is 30 days from the invoice issue date.

X. METHOD OF COMMUNICATION BETWEEN THE BUYER AND THE SELLERS, PERSONS AUTHORIZED TO CONTACT THEM

10.1. In the proceedings, statements, applications, notices and information shall be submitted by the Buyer and the Seller in Polish or English.



- 10.2. All notices, statements, requests and information transmitted in electronic form shall require, at the request of either party, immediate confirmation of receipt.
- 10.3. In the absence of an acknowledgment of receipt of correspondence by the Seller, the Buyer shall presume that the correspondence sent by the Buyer to the email address provided by the Seller has been delivered to the Buyer in such a way as to enable the Buyer to become acquainted with its contents.
- 10.4. Correspondence related to this inquiry should be addressed to the e-mail address: beata.zywicka@polpharma.com
- 10.5. In correspondence related to this inquiry, the Seller should use the procedure number: **SEMA 70/PR113719/2025**
- 10.6. The person authorized to communicate with the Seller is **Ms. Beata Żywicka**.
- 10.7. No verbal or telephonic information, explanations or answers to inquiries addressed to the Buyer are provided.
- 10.8. Any questions regarding this inquiry should be submitted by email to the address indicated above no later than 3 days before the deadline for submission of bids.
- 10.9. Responses to questions and the detailing of the Inquiry resulting from questions from potential Sellers will be sent to the entity that sent the question.

XI. PROCEDURE FOR EVALUATION OF TENDERS AND ANNOUNCEMENT OF RESULTS

- 11.1. In the course of examination and evaluation of bids, the Buyer may request from the Seller supplements (if this does not violate competitiveness) and clarifications regarding the content of submitted bids. He may also request correction of obvious mistakes and calculation errors.
- 11.2. The Buyer reserves the right to check, in the course of evaluating the offer, the credibility of the documents, statements, lists, data and information presented by the Sellers.
- 11.3. If two or more Sellers obtain the same number of points, the bid with the most favorable environmental and climate impact will be selected. For this purpose, the Buyer has the right to call on the Bidders whose bids received the highest final number of points to supplement their bids by providing the information indicated by the Buyer regarding the environmental impact of the subject of the bid.
- 11.4. **The Procuring Entity reserves the right to negotiate bids** with all bidders whose bids meet the specifications, especially if the price offered by the Bidders exceeds the budget allocated by the Procuring Entity for the execution of the contract.
- 11.5. Until the deadline for submission of bids, the Procuring Entity reserves the right to amend or supplement the contents of this price inquiry.
- 11.6. The Procuring Entity reserves the right to terminate the proceedings without selecting a Contractor, without giving any reason. Bidders shall not be entitled to claim reimbursement of costs incurred in the preparation of the bid.
- 11.7. If the supplier's income earned in connection with the execution of the project is subject to withholding tax in Poland, then ZF Polpharma S.A. is required by law to withhold withholding tax from the supplier's remuneration and pay it to the Polish tax authorities (**the remuneration includes withholding tax**).
- 11.8. Transfer to the Ordering Party (as part of the agreed remuneration) all exclusive rights and all transferable other rights to intangible assets that will arise in connection with the performance of the subject matter of the contract (hereinafter: "Intellectual Property Rights"). Thus, all Intellectual Property Rights created in connection with the performance of the contract shall become the exclusive property of the Ordering Party. Intellectual Property Rights, shall include both "work", "inventive design" and "know-how", which shall be defined in detail in the body of the contract.

XII. AMENDMENT TO THE CONTENT OF THE AGREEMENT

- 12.1. The Contracting Authority reserves the **right to make significant changes to the provisions of the Agreement** for the offered services in relation to the content of the offer on the basis of which the Contractor was selected, in the following scope and situations:



- 12.1.1. changes in the law, to the extent affecting the implementation of the Agreement (in particular, changes in VAT rates);
- 12.1.2. improve the technical parameters of the subject of the Agreement, resulting from the update of solutions due to technological progress, without affecting the gross lump sum price
- 12.1.3. extension of the term of the Contract as a result of the need to perform additional work, the performance of which is necessary for the proper execution of the Contract, and the performance of which the Contracting Authority, acting with due diligence, could not have foreseen earlier, subject to Section XII.1.7 below;
- 12.1.4. extension of the deadline for execution of the Agreement as a result of force majeure, together with all the consequences occurring in connection with the extension of this deadline
- 12.1.5. Extend the contract completion date if, due to the testing process, there are delays in the delivery of test samples and other required materials or information
- 12.1.6. changes in the parameters of the subject matter of the Agreement, not leading to changes in the nature of the Agreement - technological changes, in particular: the need to implement the Agreement using other technical/technological, material solutions than those indicated in the Request for Proposal, in a situation where the use of the provided solutions would threaten non-performance or faulty performance of the Agreement, subject to item XII.1.8. below;
- 12.1.7. changes relate to the performance of additional supplies or services of the Contractor, not covered by the Contract, if they have become necessary and the following conditions are met together:
- change of the Contractor cannot be made for economic or technical reasons, in particular concerning interchangeability or interoperability of equipment, services or installations, ordered under the basic subject of the Contract,
 - change of the Contractor would cause substantial inconvenience or a significant increase in costs for the Ordering Party,
 - the value of each subsequent change does not exceed 50% of the net value of the original net subject of the Agreement;
- 12.1.8. the change does not lead to a change in the nature of the Agreement and the following conditions have been met together:
- the need to amend the Contract is due to circumstances that the Contracting Authority, acting with due diligence, could not foresee,
 - the value of the change does not exceed 50% of the value of the original net subject of the Agreement;
- 12.2.** The contractor is to be replaced by a new contractor:
- as a result of a merger, demerger, transformation, bankruptcy, restructuring or acquisition of the Contractor or its enterprise, provided that the new contractor meets the conditions for participation in the proceedings, there are no grounds for exclusion against it and it does not involve other material changes to the Contract,
 - as a result of the Ordering Party's assumption of the Contractor's obligations to its subcontractors.
- 12.3.** The Contracting Authority also provides for **the possibility of making non-substantive changes to the provisions of the Agreement** in relation to the content of the offer on the basis of which the Contractor was selected.
- 12.4.** Amendments to the Agreement will be made in the form of annexes signed by both Parties, and the possibility of their introduction is subject to approval by the Ordering Party.

XIII. LIST OF ANNEXES

The following documents are attached to this Price Request:

Appendix Designation	Name of the Appendix
Appendix 1	Sample of Bid Form
Appendix 2	Template of statement of compliance with the conditions set out in the price inquiry



Appendix No. 1 to the Price Request No. SEMA 70/PR113719/2025

BID FORM

Bidder:

Full name (company) or first and last name	
Registered office/place of residence/address of main place of business	
The e-mail address to which the Employer should send correspondence related to the price inquiry	
NIP	
REGON	
Phone	
Contact person for the Purchaser	

We offer to perform the subject of the contract for the *provision of research services* in accordance with the requirements of the Price Request:

Order completion date:

..... weeks (maximum 8 weeks) calculated from the date of delivery of all samples to the laboratory to the date of delivery of the report by the bidder for **method** development

..... weeks (maximum 12 weeks) calculated from the date of delivery of all samples to the laboratory to the date of delivery of the validation report by the bidder for **method** validation

..... weeks (maximum 8 weeks) counted from the date of delivery of samples to the laboratory to the date of delivery of the work report for comparative tests

..... weeks (maximum 8 weeks) counted from the date of delivery of samples to the laboratory to the date of delivery of the work report for routine analyses

No	Price Inquiry Subject		Total Net Value PLN / EUR / USD / GBP *	Total Gross Value PLN / EUR / USD / GBP *
1	Development of analytical methods			
	- differential scanning calorimetry DSC	1A		
	- CD circular dichroism	1B		
	- Sedimentation velocity with SV-AUC ultracentrifugation	1C		
	- Nuclear magnetic resonance (1D NMR, 2D NMR)	1D		



AGENCJA
BADAŃ
MEDYCZNYCH



No	Price Inquiry Subject		Total Net Value PLN / EUR / USD / GBP *	Total Gross Value PLN / EUR / USD / GBP *
TOTAL PRICE FOR METHOD DEVELOPMENT (1A+1B+1C+1D):				

No	Subject of the price inquiry		number of measurements	Net price PLN/EUR/USD / GBP * per one measurement	Total net value PLN / EUR / USD / GBP *	Total gross value PLN / EUR / USD / GBP *
2	Validation of analytical methods					
	- differential scanning calorimetry DSC	2A	validation (as a minimum validation scope)			
		2B	additional test (1 sample)			
	- - CD circular dichroism	2C	validation (as a minimum validation scope)			
		2D	additional test (1 sample)			
	- Sedimentation velocity with SV-AUC ultracentrifugation	2E	validation (as a minimum validation scope)			
		2F	additional test (1 sample)			



AGENCJA
BADAŃ
MEDYCZNYCH



No	Subject of the price inquiry		number of measurements	Net price PLN/EUR/USD / GBP * per one measurement	Total net value PLN / EUR / USD / GBP *	Total gross value PLN / EUR / USD / GBP *
	- Nuclear magnetic resonance (1D NMR, 2D NMR)	2G	validation (as a minimum validation scope)			
		2H	additional test (1 sample)			
TOTAL PRICE FOR METHOD VALIDATION MINIMUM RANGE (2A+2C+2E+2G):						
TOTAL PRICE FOR METHOD VALIDATION ADDITIONAL RANGE (2B+2D+2F+2H):						
3	Comparative study against a reference product for using orthogonal techniques:					
	- DSC <i>reference</i> and <i>test product</i>	3A	1 study for 6 series (minimum range)			
		3B	1 test for 1 series (additional order)			
	- CD <i>reference</i> and <i>test product</i>	3C	1 test for 6 series (minimum range)			
		3D	1 test for 1 series (additional order)			
	- Reference and test product sedimentation velocity by SV-AUC	3E	1 test for 6 series (minimum range)			



AGENCJA
BADAŃ
MEDYCZNYCH



No	Subject of the price inquiry		number of measurements	Net price PLN/EUR/USD / GBP * per one measurement	Total net value PLN / EUR / USD / GBP *	Total gross value PLN / EUR / USD / GBP *
		3F	1 test for 1 series (additional order)			
	- <i>Reference product/active substance</i> and <i>test</i> nuclear magnetic resonance (1D NMR, 2D NMR)	3G	1 test for 6 series (minimum range)			
		3H	1 test for 1 series (additional order)			
TOTAL PRICE FOR COMPARATIVE TESTINF OF SAMPLES MINIMUM RANGE (3A+3C+3E+3G) :						
TOTAL PRICE FOR COMPARATIVE TESTINF OF SAMPLES ADDITIONAL RANGE (3B+3D+3F+3H):						
4	Conducting routine examinations non-GMP					
	Examination of the material sample during the project period using the DSC technique	4A	1 test for 1 series (minimum range)			
	Examination of the material sample during the project period using the DSC technique	4B	1 test for 1 subsequent series (additional order)			
	Examination of a sample of material during the project period using the CD technique	4C	1 test for 1 series (minimum range)			
	Examination of a sample of material during the project period using the CD technique	4D	1 test for 1 subsequent series (additional order)			



AGENCJA
BADAŃ
MEDYCZNYCH



No	Subject of the price inquiry		number of measurements	Net price PLN/EUR/USD / GBP * per one measurement	Total net value PLN / EUR / USD / GBP *	Total gross value PLN / EUR / USD / GBP *
	Examination of the material sample during the project period using the SV-AUC technique	4E	1 test for 1 series (minimum range)			
	Examination of the material sample during the project period using the SV-AUC technique	4F	1 test for 1 subsequent series (additional order)			
	Examination of the material sample during the project period using 1D NMR, 2D NMR techniques	4G	1 test for 1 series (minimum range)			
	Examination of the material sample during the project period using 1D NMR, 2D NMR techniques	4H	1 test for 1 subsequent series (additional order)			
TOTAL PRICE FOR ROUTINE TESTING NON-GMP MINIMUM RANGE (4A+4C+4E+4G):						
TOTAL PRICE FOR ROUTINE TESTING NON-GMP ADDITIONAL RANGE (4B+4D+4F+4H):						
5	Conducting routine examinations GMP					
	Examination of the material sample during the project period using the DSC technique	5A	1 test for 1 series (minimum range)			
	Examination of the material sample during the project period using the DSC technique	5B	1 test for 1 subsequent series (additional order)			
	Examination of a sample of material during the project period using the CD technique	5C	1 test for 1 series (minimum range)			



AGENCJA
BADAŃ
MEDYCZNYCH



No	Subject of the price inquiry		number of measurements	Net price PLN/EUR/USD / GBP * per one measurement	Total net value PLN / EUR / USD / GBP *	Total gross value PLN / EUR / USD / GBP *
	Examination of a sample of material during the project period using the CD technique	5D	1 test for 1 subsequent series (additional order)			
	Examination of the material sample during the project period using the SV-AUC technique	5E	1 test for 1 series (minimum range)			
	Examination of the material sample during the project period using the SV-AUC technique	5F	1 test for 1 subsequent series (additional order)			
	Examination of the material sample during the project period using 1D NMR, 2D NMR techniques	5G	1 test for 1 series (minimum range)			
	Examination of the material sample during the project period using 1D NMR, 2D NMR techniques	5H	1 test for 1 subsequent series (additional order)			
TOTAL PRICE FOR ROUTINE TESTING GMP MINIMUM RANGE (5A+5C+5E+5G):						
TOTAL PRICE FOR ROUTINE TESTING GMP ADDITIONAL RANGE (5B+5D+5F+5H):						
SUMMARY OF MINIMUM ORDER ITEMS OF ALL STAGES (1A,B,C,D,+2A,C,E,G+3A,C,E,G+4A,C,E,G+5A,C,E,G):						

No	Subject of the price inquiry		number of measurements	Net price PLN/EUR/USD / GBP * per one measurement	Total net value PLN / EUR / USD / GBP *	Total gross value PLN / EUR / USD / GBP *
SUMMARY OF ITEMS FOR ADDITIONAL ORDERS OF ALL STAGES (2B,D,F,H+3B,D,F,H+4B,D,F,H + 5B,D,F,H):						
SUMMARY OF MINIMUM ORDER ITEMS (1A,B,C,D,+2A,C,E,G+3A,C,E,G+4A,C,E,G+ 5A,C,E,G) AND SUMMARY OF ITEMS FOR ADDITIONAL ORDERS (2B,D,F,H+3B,D,F,H+4B,D,F,H + 5B,D,F,H) OF ALL STAGES: THE VALUE ENTERED IN THE SUMMARY WILL BE TAKEN FOR EVALUATION IN ACCORDANCE WITH POINT. VIII OF THE INVITATION						

*delete as necessary, select the correct currency.

At the same time, we declare that:

- we have familiarized ourselves with the Request for Quotation and its attachments and do not raise any objections, and we have acquired the necessary information to prepare our offer,
- The price includes a lump sum remuneration for all the Seller's obligations necessary to complete the subject of the Price Request,
- We consider ourselves bound by this bid for a period of 90 calendar days from the deadline for submission of bids ,
- d. By submitting this offer, we declare that we meet the participation requirements specified in Section V of the request for quotation.
- The invoice payment term is at least 30 days.

.....
(place and date)

.....
(signature of the person(s) authorized to make a statement of intent on behalf of the Bidder)



Appendix No. 2 to the Price Request No. SEMA 70/PR113719/2025

STATEMENT OF COMPLIANCE WITH THE CONDITIONS SET OUT IN THE PRICE INQUIRY

... .. (Company/Contractor) declares that it meets the terms and conditions specified in the request for proposals in accordance with the table below:

- i. We have at least 3 years of knowledge and experience in conducting NMR studies on polypeptides.
- ii. We have at least 3 years of knowledge and experience in conducting CD, DSC, and SV-AUC studies on polypeptides.
- iii. Upon completion of all work, we will provide:
 - a. A report containing a description of the method, the results of the analyzed samples, and conclusions.
 - b. Raw data related to the conducted studies.

.....
(place and date)

.....
(signature)